News und Analysen

Forget stealth fighter jets, drones, and orbital, Earth-observing spy satellites. If you ask the U.S. Army, the future of Command, Control, Communications, Computers, Intelligence, Surveillance, and

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions.

Three Motley Fool contributors think

Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust underlying operations. Also, reinvesting the dividend can

One of the foundational pieces of the fast-growing artificial intelligence (AI) market has been the advanced semiconductors that make AI tools possible. Nvidia (NASDAQ: NVDA) has garnered the most

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in

Artificial intelligence (AI) chip stocks are having a torrid time on the market in 2025, and that's not surprising. The sector has been hit hard by multiple headwinds of late, such as the viability

U.S. telecommunications giant AT&T (NYSE: T) has lulled investors to sleep with its poor performance over most of the past decade. But the stock has enjoyed a face-ripping rally over the past year

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. Investors greeted this positively, rewarding the company with a

Anytime a company within the chronically struggling marijuana industry sees a leap in stock price, it's notable. That happened on Thursday with top Canadian cannabis company Tilray Brands (NASDAQ:

Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still

Uncertainty over the future of the U.S. economy has roiled the stock market, causing many stocks to sink. In this environment, telecom stocks present a potential reprieve. Society's dependence on

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit

Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they

Lumen (NYSE: LUMN) stock got hit hard in Tuesday's trading. Its share price was down 10% just before market close on news that the company could wind up selling one of its units to AT&T. The stock

Image source: The Motley Fool.

CorMedix (NASDAQ: CRMD)Q4 2024 Earnings CallMar 25, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of semiconductor heavyweights Taiwan Semiconductor Manufacturing (NYSE: TSM), Advanced Micro Devices (NASDAQ: AMD), and Monolithic Power Systems (NASDAQ: MPWR) were rallying today, up 2.7%

Palantir Technologies (NASDAQ: PLTR) has been one of the hottest artificial intelligence (AI) stocks on Wall Street, but it has become a bit overheated. This has caused the stock to sell off 30%

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year. Still, some companies are performing